Degron Eyes Deals For Novel Molecular Glue Degrader Assets

$1bn+ Takeda Alliance Last Year

Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.

Molecular glue degraders, an emerging drug class expected to unlock the therapeutic potential of historically hard-to-drug targets, have made progress by leaps and bounds over the past few years. (Shutterstock)

Degron Therapeutics, a Chinese specialist in molecular glue degraders (MGD), is looking beyond technology-based, compound screening collaborations with multinational big pharmas.

MGDs, an emerging drug class expected to unlock the therapeutic potential of historically hard-to-drug targets, have made progress by leaps...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Henlius CEO Details PD-L1 ADC’s Path To 1L Mono/Combo Therapy

16 Jun 2025

• By Dexter Jie Yan

Henlius is investigating the optimum dose for its PD-L1-targeting antibody-drug conjugate HLX43 to support potential first-line use, its CEO explains to Scrip.